Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851734 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
A Phase 1 study of Keratoconjunctivitis Sicca, sponsored by Lux Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00851734 is a Phase 1 study of Keratoconjunctivitis Sicca that has completed, run by Lux Biosciences. The registered enrollment target is 35 participants, below the 168-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00851734, a Phase 1 study of Keratoconjunctivitis Sicca, has completed, sponsored by Lux Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
Conditions Studied
Interventions
- DRUG voclosporin ophthalmic solution
Study Locations (1)
Pennsylvania
- Product Investigations - Conshohocken
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851734
The ClinicalTrials.gov registry entry for NCT00851734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (79% lower). The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratoconjunctivitis Sicca appearing as the primary indexed condition, and to 1 intervention - of which voclosporin ophthalmic solution is the first listed.
NCT00851734 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00851734 about?
NCT00851734 is a clinical study titled "A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)". This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
What is the current status of trial NCT00851734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2009-02. Estimated completion is 2009-04.
What conditions does trial NCT00851734 study?
This clinical trial studies the following conditions: Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT00851734?
The interventions under investigation include: voclosporin ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00851734?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00851734 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconjunctivitis Sicca
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
COMPLETED
-
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
COMPLETED · Phase 3
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.